Literature DB >> 2788659

Interleukin-2 (rIL-2)-induced lymphokine-activated killer (LAK) cells and their precursors express the VGO1 antigen.

J F Denegri1, J Peterson, P Tilley.   

Abstract

Precursor and effector cells of recombinant interleukin-2 (r-IL-2)-induced lymphokine-activated killer (LAK) activity were investigated for their expression of VGO1. Peripheral blood lymphocytes (PBL) from normal donors were purified and separated in a FACS 420 into VGO1+- and VGO1- cell fractions before and after culture for 96 hr with 100 U/ml of r-IL-2. Their lytic activity against K 562 and Daudi cells was measured in a 51Cr release assay. The majority, if not all, of the LAK effector and precursor cells was VGO1+ lymphocytes. The expression of VGO1 by LAK precursor cells remained stable under the culture conditions used in our experiments. VGO1- lymphocytes cultured with r-IL-2 demonstrated neither LAK-induced activity nor expression of VGO1 antigen.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2788659     DOI： 10.1007/bf00918668

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.317


  27 in total

1.  A T-cell receptor gamma/CD3 complex found on cloned functional lymphocytes.

Authors:  J Borst; R J van de Griend; J W van Oostveen; S L Ang; C J Melief; J G Seidman; R L Bolhuis
Journal:  Nature       Date:  1987 Feb 19-25       Impact factor: 49.962

2.  Lymphokine-activated killer cells: a new approach to immunotherapy of cancer.

Authors:  S Rosenberg
Journal:  J Natl Cancer Inst       Date:  1985-10       Impact factor: 13.506

3.  Interleukin-2 augments natural killer cell activity.

Authors:  C S Henney; K Kuribayashi; D E Kern; S Gillis
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

4.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

5.  Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.

Authors:  S Ferrini; S Miescher; M R Zocchi; V von Fliedner; A Moretta
Journal:  J Immunol       Date:  1987-02-15       Impact factor: 5.422

6.  Direct evidence for the role of LGL in the inhibition of experimental tumor metastases.

Authors:  T Barlozzari; J Leonhardt; R H Wiltrout; R B Herberman; C W Reynolds
Journal:  J Immunol       Date:  1985-04       Impact factor: 5.422

7.  Induction of NK cell activity against fresh human leukemia in culture with interleukin 2.

Authors:  E Lotzová; C A Savary; R B Herberman
Journal:  J Immunol       Date:  1987-04-15       Impact factor: 5.422

8.  Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1.

Authors:  B Perussia; S Starr; S Abraham; V Fanning; G Trinchieri
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

9.  Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission.

Authors:  A Adler; P A Chervenick; T L Whiteside; E Lotzová; R B Herberman
Journal:  Blood       Date:  1988-03       Impact factor: 22.113

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.